A novel use of intratympanic dexamethasone for intractable posterior canal benign paroxysmal positional vertigo: report of two cases
- PMID: 30486912
- DOI: 10.1017/S0022215118002037
A novel use of intratympanic dexamethasone for intractable posterior canal benign paroxysmal positional vertigo: report of two cases
Abstract
Background: Benign paroxysmal positional vertigo is a common inner-ear pathology, characterised by episodic vertigo lasting for a few seconds that is associated with sudden change in the head position. Benign paroxysmal positional vertigo is treated with canalolith repositioning manoeuvres. Intractable vertigo describes a small group of patients who either do not improve with canalolith repositioning manoeuvres (persistent cases) or who relapse after improvement of initial symptoms (recurrent cases). These cases are difficult to treat and may have to be treated surgically.Case reportsThis paper reports two cases of intractable posterior canal benign paroxysmal positional vertigo that were treated with intratympanic dexamethasone injections on an interval basis.
Results: Both patients showed good control of their vertiginous symptoms, with negative Dix-Hallpike test findings following the intervention.
Conclusion: The findings support an underlying inflammatory pathology in intractable benign paroxysmal positional vertigo; intratympanic steroids should be considered as an intermediate option before proceeding to a definitive surgical intervention.
Keywords: Benign Paroxysmal Positional Vertigo; Dexamethasone; Injections; Middle Ear; Steroids.
Similar articles
-
Role of Intratympanic Dexamethasone for Intractable Posterior Canal Benign Paroxysmal Positional Vertigo.Int Tinnitus J. 2021 Mar 1;25(1):107-111. doi: 10.5935/0946-5448.20210019. Int Tinnitus J. 2021. PMID: 34410088 Review.
-
Nystagmus discordance with 2-dimensional videonystagmography in posterior semicircular canal benign paroxysmal positional vertigo.Otolaryngol Head Neck Surg. 2015 Apr;152(4):724-8. doi: 10.1177/0194599814564373. Epub 2015 Jan 5. Otolaryngol Head Neck Surg. 2015. PMID: 25560403
-
A Pilot Study Using Intratympanic Methylprednisolone for Treatment of Persistent Posterior Canal Benign Paroxysmal Positional Vertigo.J Int Adv Otol. 2016 Dec;12(3):321-325. doi: 10.5152/iao.2016.3014. Epub 2016 Nov 28. J Int Adv Otol. 2016. PMID: 27897129 Clinical Trial.
-
Effect of repetition of Semont's manoeuvre on benign paroxysmal positional vertigo of posterior semicircular canal.Acta Otorhinolaryngol Ital. 2003 Dec;23(6):428-35. Acta Otorhinolaryngol Ital. 2003. PMID: 15198044
-
Benign paroxysmal positional vertigo and its variants.Handb Clin Neurol. 2016;137:241-56. doi: 10.1016/B978-0-444-63437-5.00018-2. Handb Clin Neurol. 2016. PMID: 27638076 Review.
Cited by
-
Causes and treatment of idiopathic benign paroxysmal positional vertigo based on endocrinological and other metabolic factors.J Otol. 2020 Dec;15(4):155-160. doi: 10.1016/j.joto.2020.04.001. Epub 2020 Jun 1. J Otol. 2020. PMID: 33293917 Free PMC article. Review.
-
Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway.Biol Res. 2022 Apr 4;55(1):16. doi: 10.1186/s40659-022-00385-3. Biol Res. 2022. PMID: 35379352 Free PMC article.
-
Benign Paroxysmal Positional Vertigo: Is It Really an Otolith Disease?J Int Adv Otol. 2022 Jan;18(1):62-70. doi: 10.5152/iao.2022.21260. J Int Adv Otol. 2022. PMID: 35193848 Free PMC article. Review.
-
Surgical treatment of otogenic vertigo.Eur Arch Otorhinolaryngol. 2025 May 23. doi: 10.1007/s00405-025-09467-w. Online ahead of print. Eur Arch Otorhinolaryngol. 2025. PMID: 40407891 Review.
-
Benign Positional Paroxysmal Vertigo Treatment: a Practical Update.Curr Treat Options Neurol. 2019 Dec 5;21(12):66. doi: 10.1007/s11940-019-0606-x. Curr Treat Options Neurol. 2019. PMID: 31807976 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical